Biologics Beckon: Biocon, Mylan Strike Deal; Combine To Take Teva, Sandoz Head-on
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Prospects for strong growth in the global generic biologics space in the next 10 years has brought together the world's third-largest generic drug maker Mylan and India's biotechnology company Biocon. The two signed a comprehensive deal that will share development and certain other costs to bring biologic drugs to the market
You may also be interested in...
ANALYSIS: What Would A Teva-Mylan Deal Mean For India?
The situation is still fluid on a possible merger between Teva and Mylan and will likely see a few quick and dramatic turns over the next few weeks. In the event a deal does click, it would have a significant impact on the two firms’ Indian businesses and also Indian generic manufacturers more generally.
India’s Biocon Wins 1st Biosimilar Approval Of Herceptin; Will Launch Before March 2014
As the decks are cleared for an India launch of trastuzumab, Biocon and its global partner Mylan will be watched closely by both local and global competitors. The market impact in India will be most significant in terms of price, and it will test if Roche has played its cards right by aligning with local company Emcure.
India’s Biocon Wins 1st Biosimilar Approval Of Herceptin; Will Launch Before March 2014
As the decks are cleared for an India launch of trastuzumab, Biocon and its global partner Mylan will be watched closely by both local and global competitors. The market impact in India will be most significant in terms of price, and it will test if Roche has played its cards right by aligning with local company Emcure.